Radotinib for CML patients after prior TKI failure
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have chronic-phase Ph+ CML and your prior TKI treatment failed or you could not tolerate it (including imatinib).
- Your performance status is ECOG 0, 1, or 2 (you can do some daily activities).
- Your blood counts and body organ tests fit the study limits, including enough platelets and acceptable liver and kidney tests.
- You do not have blast crisis or accelerated-phase CML at screening, and you do not have a specific mutation called T315I.
- You can follow pregnancy prevention rules if you could become pregnant, and you can provide consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This early-phase study tests HS-10382 in adults with chronic myeloid leukemia (CML) whose leukemia is resistant to or not tolerated of standard pills. It aims to see if the drug can control CML when earlier treatment hasn’t worked for you.
This trial tests if lowering the dose of radotinib is safe and effective for adults newly diagnosed with a certain type of leukemia (chronic phase CML). It may help control the disease while reducing side effects.
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.